The evolution of coronary stents.
Peter McKavanagh, George Zawadowski, Naveed Ahmed...
https://pubmed.ncbi.nlm.nih.gov/29381087/Actively Recruiting
Led by National Institute of Cardiovascular Diseases, Pakistan · Updated on 2025-11-14
496
Participants Needed
1
Research Sites
1 weeks
Total Duration
Researchers are evaluating the use of drug-coated balloons DCB compared to drug-eluting stents DES in young adults under 50 years old who have experienced ST Elevation Myocardial Infarction STEMI. This randomized controlled trial aims to determine if DCBs, which do not leave a permanent implant, can reduce risks associated with stents such as restenosis, thrombosis, and the need for prolonged dual antiplatelet therapy. The study is particularly important due to the high rate of STEMI in young adults in South Asia, especially at the National Institute of Cardiovascular Diseases NICVD in Karachi. The trial enrolls 496 patients randomized equally to receive either a paclitaxel-coated balloon DCB inflated for 30 seconds or a standard second-generation drug-eluting stent DES during primary percutaneous coronary intervention PCI. A pilot phase with 50 patients will first assess safety outcomes like abrupt vessel closure and bailout stenting. Participants in both groups receive ticagrelor twice daily for one month, followed by continued dual antiplatelet therapy. An intravascular ultrasound substudy will evaluate vessel remodeling and late lumen loss in 100 patients treated with DCB at baseline and six months. Participants will be monitored through clinical visits and phone follow-ups at 14 days, 30 days, 3, 6, and 12 months after the procedure. Researchers will assess outcomes including vessel-oriented cardiac events, bleeding, blood flow quality, residual narrowing, and need for additional stenting. The main goal is to compare one-year vessel-oriented composite endpoints such as cardiovascular or all-cause death, heart attack in the treated vessel, or repeat procedures. Safety and data quality are overseen by independent boards, and the total study duration per participant is 12 months.
CONDITIONS
DCB vs. DES in Young STEMI Patients: The DCB-STEMI Trial
A
Abdul Hakeem, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Cardiovascular Diseases, Pakistan
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit (in-person)
Duration - Single procedure day
Participants undergo primary percutaneous coronary intervention (PCI) using either a drug coated balloon or a drug eluting stent to treat STEMI.
1 procedure visit (in-person)
Duration - Up to 12 months
Participants receive post-PCI care including dual antiplatelet therapy (DAPT) with ticagrelor for up to 1 year to prevent complications.
Clinical follow-up visits or phone calls at 14 days, 30 days, 3 months, 6 months, and 12 months
Duration - 12 months
Participants are monitored for clinical events such as death, myocardial infarction, bleeding, and vessel-related outcomes during the 1-year study period.
Follow-up visits or phone calls at scheduled intervals up to 12 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Peter McKavanagh, George Zawadowski, Naveed Ahmed...
https://pubmed.ncbi.nlm.nih.gov/29381087/Ke Nan Huang, Sonia M Grandi, Kristian B Filion...
https://pubmed.ncbi.nlm.nih.gov/23830291/Norman Mangner, Ahmed Farah, Marc-Alexander Ohlow...
https://pubmed.ncbi.nlm.nih.gov/35000455/National Institute of Cardiovascular Diseases, Pakistan
Lead Sponsor